7,723 336,927 COMPREHENSIVE INCOME $7,994,446 $12,083,773 $30,944,456 $27,702,961 WEIGHTED AVERAGE NUMBER OF SHARES: Basic 11,524,297 10,435,049 11,104,025 10,061,326 Diluted 14,998,414 14,898,332 15,135,130 14,484,830 EARNINGS PER SHARE: Basic $0.62 $1.10 $2.69 $2.87 Diluted $(0.39) $(0.28) $1.36 $0.09 JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.) CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Twelve Months Ended June 30, 2010 2009 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $29,850,355 $28,880,264 Loss from discontinued operations 243,792 1,781,946 Income from continuing operations 30,094,147 30,662,210 Adjustments to reconcile net income to cash provided by (used in) operating activities: Depreciation 823,087 679,507 Amortization of intangible assets 1,585,141 735,427 Amortization of debt issuance costs 801,034 680,276 Amortization of debt discount 14,823,337 4,006,868 Loss from issuance of shares for in lieu of interest 318,936 -- Interest payment with shares in lieu of cash 4,457 -- Bad debt (recovery) expense 642,499 538,069 Loss on sale of marketable securities 406,346 473,303 Unrealized (gain) loss on investments (150,525) 229,425 Other non-cash settlement (income) expense -- (20,000) Change in fair value of derivative liabilities (14,631,455) -- Stock based compensation 531,750 -- Amortization of stock based compensation 135,104 106,815 Changes in operating assets and liabilities Accounts receivable (14,450,712) 4,651,284 Accounts receivable - related parties -- 676,579 Inventories 1,089,795 792,293 Other receivables 154,018 (21,038) Other receivables- related parties (322,674) -- Advances to suppliers (22,856) 1,495,805 Accounts payable (2,057,625) 3,795,084 Refundable security deposits due to distributors (293,340) 4,102,000 Other payables 1,716,847 (1,534,740) Other payables - related parties 16,571 (86,692) Accrued liabilities 4,221,119 1,182,018 Liabilities assumed from reorganizatio
'/>"/>SOURCE Jiangbo Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 20102.
Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets3.
Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference4.
Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer5.
Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market6.
Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 20107.
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 20108.
Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 20109.
Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory10.
Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate11.
Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results